Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30513029 | 1.00 | P2RY1 (0.68) | P2RY1YTHDC1 | |
| SCHEMBL29427723 | 0.89 | P2RY1 (0.56) | P2RY1YTHDC1 | |
| SCHEMBL31425733 | 0.82 | P2RY1 (0.53) | P2RY1YTHDC1 | |
| SCHEMBL14509185 | 0.81 | P2RY1 (1.00) | P2RY1 | |
| SCHEMBL23867126 | 0.77 | P2RY1 (1.00) | P2RY1YTHDC1 | |
| SCHEMBL3675889 | 0.75 | P2RY1 (0.46) | P2RY1YTHDC1 | |
| SCHEMBL20774171 | 0.72 | P2RX7 (0.49) | P2RY1YTHDC1 | |
| SCHEMBL9583418 | 0.71 | P2RY1 (0.52) | P2RY1YTHDC1 | |
| SCHEMBL14509250 | 0.71 | P2RY1 (1.00) | P2RY1YTHDC1 | |
| SCHEMBL9583890 | 0.70 | YTHDC1 (0.60) | P2RY1YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772040-B2 | Apparatus and method of platelet multi-function analysis, and micro stirring chip | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2014-07-08 | — | — | US | claimed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | claimed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | claimed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20230279048-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-09-07 | — | — | US | disclosed |
| US-11518782-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3838293-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | Tissuetech, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-2872181-B1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200308219-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-10-01 | — | — | US | disclosed |
| US-10717763-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10597722-B2 | Predictive analysis for myocardial infarction | SCRIPPS HEALTH (US) | 2020-03-24 | — | — | US | disclosed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010042548-A2 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100093636-A1 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20070254324-A1 | Method for determination of platelet function under flow conditions | DADE BEHRING MARBURG GMBH | 2007-11-01 | — | — | US | disclosed |
| US-20070254325-A1 | Method and device for the determination of platelet function under flow conditions | DADE BEHRING MARBURG GMBH | 2007-11-01 | — | — | US | disclosed |
| EP-1850134-A1 | Method and Apparatus for the determination of the Thromboyte function and flow conditions | Dade Behring Marburg GmbH (DE) | 2007-10-31 | — | — | EP | disclosed |
| EP-1850135-A1 | Method for determining the thrombocyte function and flow conditions | Dade Behring Marburg GmbH (DE) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | TNNI3, TNNT2, FABP3 | P2RY1 352/4885YTHDC1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.